Background: The treatment of hepatitis C virus (HCV) infection is rapidly evolving to interferon (IFN) and ribavirin (RBV) free treatment with directly acting antiviral agents (DAAs). The impact of DAAs on HCV treatment adherence in HIV/HCV co-infected populations has not been extensively evaluated. We compared adherence rates of the IFN and RBV free DAA regimen of ledipasvir/sofosbuvir (LDV/SOF) between HCV mono-infected and HIV/HCV co-infected patients.
Methods: Participants were representative of the urban Washington D.C. cohort and were HCV treatment naïve, genotype 1 study subjects from two National Institute of Allergy & Infectious Diseases (NIAID) phase 2 clinical trials (Synergy A: HCV mono-infected participants, n=20, and Eradicate: HIV/HCV co-infected participants, antiretroviral (ARV) naïve, n=13, on combination ARV therapy, n=37). Patients were treated with LDV (90 mg) + SOF (400 mg) as a fixed dose combination once daily for twelve weeks. Adherence was measured using three tools: MEMS (Medication Event Monitoring System) caps, pill counts, and patient report. Adherence over time was compared using Wilcoxon T test. Analyses were performed using PRISM 6.0 (Graphpad).
Results: Patients enrolled were predominately African American (83%) and male (73%), with a median age of 59 years. Patients in all three-treatment groups had prompt viral load decline associated with high adherence rates. Only twelve out of the sixty patients (20%) missed 4 or more pills. However, patient adherence significantly decreased from baseline – week 4 compared to week 8 – 12 in all three groups [HCV mono-infected (p=0.02), HIV/HCV ARV naive (p=0.01), and HIV/HCV ARV treated patients (p=0.01)].
Conclusions: Adherence to the single daily tablet of LDV/SOF in this urban population was high and coupled with complete HCV viral suppression. However, adherence significantly declined over the course of treatment, suggesting that shorter duration DAA therapies should be evaluated for HCV treatment efficacy in this patient population.